Market Overview:
The global norepinephrine/noradrenaline market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing incidence of cardiovascular diseases and rising demand for norepinephrine/noradrenaline drugs in various applications. Based on type, the global norepinephrine/noradrenaline market is segmented into oral medication and intravenous drip. The oral medication segment is anticipated to account for a larger share of the market during the forecast period, owing to its ease of use and lower cost as compared to intravenous drip. Based on application, the global norepinephrine/noradrenaline market is segmented into acute hypotensive shock, peripheral vasodilatation shock, and others (including septic shock and anaphylactic shock). Acute hypotensive shock accounted for a major share of the market in 2017 and is projected to maintain its dominance during the forecast period. This can be attributed to increasing incidence rates of hypertension across all regions worldwide.
Product Definition:
Norepinephrine, also known as noradrenaline, is a hormone and neurotransmitter that is produced in the brain. It plays an important role in regulating the body's response to stress and helps to control heart rate, blood pressure, and other functions. Norepinephrine can also be used as a medication to treat conditions such as heart failure, depression, and narcolepsy.
Oral Medication:
Oral medications are drugs that are taken in the mouth. They may be prescribed by a doctor or they can be bought over-the-counter (OTC). The most common types of oral medications include antihistamines, analgesics, decongestants, antacids and anti-emetics among others. OTC products usually consist of tablets/lozenges or gels/creams and are available without a prescription.
Intravenous Drip:
Intravenous drip is a method of delivering medications through the veins. Medications are administered in doses which are lower than the oral dose and hence there is no need to worry about pill burden or difficulty in swallowing. Intravenous drips can be used with any medication, including opioids, benzodiazepines, anti-epileptics and others.
Application Insights:
The others segment held the largest revenue share of over 60.0% in 2017 and is anticipated to witness significant growth during the forecast period owing to its wide application in various conditions such as anxiety, hypertension, angina pectoris, arrhythmia and cardiac arrest. Increasing awareness about these drugs as a substitute for other treatment options has resulted in their increased utilization for various indications across the globe.
In addition, growing usage of norepinephrine/noradrenaline for treating symptoms of Parkinson¢â‚¬â„¢s disease such as depression and restlessness is expected to drive market growth during the forecast period. Furthermore, increasing research & development activities pertaining to these drugs are projected to positively impact industry growth over the coming years.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and increasing awareness levels are some of the factors responsible for its growth. Moreover, a rise in cases of chronic diseases such as diabetes is also expected to drive this regional market over the forecast period.
Asia Pacific is anticipated to be one of the fastest-growing regions during the forecast period owing to various factors such as improving healthcare infrastructure and economic development in emerging countries like India and China. In addition, an increase in product launches by major manufacturers coupled with growing demand for generic drugs will further propel this region’s growth over the next eight years (from 2018 to 2030). For instance, Cipla Inc., launched Norepinephrine bitartrate under brand name Mydayis (0.5 mg/mL)in March 2016; it is available as oral solution & injection formulation (BID).
Growth Factors:
- Increasing prevalence of stress and anxiety disorders
- Growing demand for better treatment options
- Rising awareness about the benefits of norepinephrine/noradrenaline therapy
- Technological advancements in norepinephrine/noradrenaline delivery systems
- increasing research and development investments
Scope Of The Report
Report Attributes
Report Details
Report Title
Norepinephrine/Noradrenaline Market Research Report
By Type
Oral Medication, Intravenous Drip
By Application
Acute Hypotensive Shock, Peripheral Vasodilatation Shock, Others
By Companies
Pfizer, Sanofi, Novartis, Sterimax, Bedford Pharmaceuticals, Teva, Amneal Biosciences, Baxter Laboratories, Mylan , Hikma Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
190
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Norepinephrine/Noradrenaline Market Report Segments:
The global Norepinephrine/Noradrenaline market is segmented on the basis of:
Types
Oral Medication, Intravenous Drip
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Hypotensive Shock, Peripheral Vasodilatation Shock, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Sanofi
- Novartis
- Sterimax
- Bedford Pharmaceuticals
- Teva
- Amneal Biosciences
- Baxter Laboratories
- Mylan
- Hikma Pharmaceuticals
Highlights of The Norepinephrine/Noradrenaline Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral Medication
- Intravenous Drip
- By Application:
- Acute Hypotensive Shock
- Peripheral Vasodilatation Shock
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Norepinephrine/Noradrenaline Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Norepinephrine and noradrenaline are neurotransmitters that are released from the nerve cells in the brain. They help to control the body's response to stress and anxiety.
Some of the key players operating in the norepinephrine/noradrenaline market are Pfizer, Sanofi, Novartis, Sterimax, Bedford Pharmaceuticals, Teva, Amneal Biosciences, Baxter Laboratories, Mylan , Hikma Pharmaceuticals.
The norepinephrine/noradrenaline market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Norepinephrine/Noradrenaline Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Norepinephrine/Noradrenaline Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Norepinephrine/Noradrenaline Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Norepinephrine/Noradrenaline Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Norepinephrine/Noradrenaline Market Size & Forecast, 2018-2028
4.5.1 Norepinephrine/Noradrenaline Market Size and Y-o-Y Growth
4.5.2 Norepinephrine/Noradrenaline Market Absolute $ Opportunity
Chapter 5 Global Norepinephrine/Noradrenaline Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Norepinephrine/Noradrenaline Market Size Forecast by Type
5.2.1 Oral Medication
5.2.2 Intravenous Drip
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Norepinephrine/Noradrenaline Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Norepinephrine/Noradrenaline Market Size Forecast by Applications
6.2.1 Acute Hypotensive Shock
6.2.2 Peripheral Vasodilatation Shock
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Norepinephrine/Noradrenaline Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Norepinephrine/Noradrenaline Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Norepinephrine/Noradrenaline Analysis and Forecast
9.1 Introduction
9.2 North America Norepinephrine/Noradrenaline Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Norepinephrine/Noradrenaline Market Size Forecast by Type
9.6.1 Oral Medication
9.6.2 Intravenous Drip
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Norepinephrine/Noradrenaline Market Size Forecast by Applications
9.10.1 Acute Hypotensive Shock
9.10.2 Peripheral Vasodilatation Shock
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Norepinephrine/Noradrenaline Analysis and Forecast
10.1 Introduction
10.2 Europe Norepinephrine/Noradrenaline Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Norepinephrine/Noradrenaline Market Size Forecast by Type
10.6.1 Oral Medication
10.6.2 Intravenous Drip
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Norepinephrine/Noradrenaline Market Size Forecast by Applications
10.10.1 Acute Hypotensive Shock
10.10.2 Peripheral Vasodilatation Shock
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Norepinephrine/Noradrenaline Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Norepinephrine/Noradrenaline Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Norepinephrine/Noradrenaline Market Size Forecast by Type
11.6.1 Oral Medication
11.6.2 Intravenous Drip
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Norepinephrine/Noradrenaline Market Size Forecast by Applications
11.10.1 Acute Hypotensive Shock
11.10.2 Peripheral Vasodilatation Shock
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Norepinephrine/Noradrenaline Analysis and Forecast
12.1 Introduction
12.2 Latin America Norepinephrine/Noradrenaline Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Norepinephrine/Noradrenaline Market Size Forecast by Type
12.6.1 Oral Medication
12.6.2 Intravenous Drip
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Norepinephrine/Noradrenaline Market Size Forecast by Applications
12.10.1 Acute Hypotensive Shock
12.10.2 Peripheral Vasodilatation Shock
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Norepinephrine/Noradrenaline Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Norepinephrine/Noradrenaline Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Norepinephrine/Noradrenaline Market Size Forecast by Type
13.6.1 Oral Medication
13.6.2 Intravenous Drip
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Norepinephrine/Noradrenaline Market Size Forecast by Applications
13.10.1 Acute Hypotensive Shock
13.10.2 Peripheral Vasodilatation Shock
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Norepinephrine/Noradrenaline Market: Competitive Dashboard
14.2 Global Norepinephrine/Noradrenaline Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Sanofi
14.3.3 Novartis
14.3.4 Sterimax
14.3.5 Bedford Pharmaceuticals
14.3.6 Teva
14.3.7 Amneal Biosciences
14.3.8 Baxter Laboratories
14.3.9 Mylan
14.3.10 Hikma Pharmaceuticals
